Summary
Left ventricular hypertrophy (LVH) has assumed an important role in clinical medicine as a result of the clinical implications of this often asymptomatic finding. Epidemiological data from the Framingham Heart Study have permitted an examination of prevalence, incidence, underlying predisposing factors and prognosis of LVH. Although LVH is an infrequent finding on the electrocardiogram, it is a forerunner of coronary disease, congestive heart failure, stroke and even peripheral arterial disease. Despite being strongly related to hypertension, LVH remains associated with excess risk for adverse cardiovascular morbid and fatal outcomes, even after adjusting for blood pressure. The risks associated with LVH are comparable with those of myocardial infarction.
The recent introduction of echocardiography at the Framingham Heart Study has permitted the development of new criteria for LVH based on M-mode determined left ventricular mass. Unlike its electrocardiographic counterpart, echocardiographically determined LVH is a common finding, occurring in over 15% of the general population. Echocardiographic LVH is related to hypertension, obesity, valvular heart disease, coronary disease and advancing age. Ambulatory ECG results in subjects with echocardiographic LVH demonstrate increased risk for ventricular arrhythmias, which have been shown in other clinical settings to predict risk for sudden cardiac death. Preliminary data from Framingham and elsewhere suggest that echocardiographic LVH is associated with increased risk for cardiovascular disease morbidity and all-cause mortality.
Similar content being viewed by others
References
Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30 year follow-up in the Framingham Study. Journal of the American Medical Association 254: 3449–3453, 1985
Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Annals of Internal Medicine 105: 173–178, 1986
Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. Journal of the American College of Cardiology 4: 1222–1230, 1984
Gubner RS, Ungerleider HE. Electrocardiographic criteria of left ventricular hypertrophy. Archives of Internal Medicine 72: 196–209, 1943
Kannel WB, Sorlie P. Left ventricular hypertrophy in hypertension: prognostic and pathogenetic implications: The Framingham Study. In Strauer (Ed.) The heart in hypertension, pp. 223–242, Springer-Verlag, Berlin, 1981
Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Heart Study. Annals of Internal Medicine 72: 813–22, 1970
Kannel WB, Levy D, Cupples LA. LVH and risk for congestive heart failure: the Framingham study. Journal of Cardiovascular Pharmacology 10 (Suppl. 6): S135, 1987
Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. American Journal of Cardiology, in press
Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. American Journal of Cardiology 59: 956–960, 1987a
Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. American Journal of Cardiology 60: 560–565, 1987b
Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Annals of Internal Medicine 108: 7–13, 1988
MacMahon SW, Wilcken DEL, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young overweight hypertensive patients. New England Journal of Medicine 314: 334–339, 1986
Panidis IP, Kotier MN, Ren JF, Mintz GS, Ross J, et al. Development and regression of left ventricular hypertrophy. Lancet 1: 1165–1168, 1984
Romhilt DW, Estes Jr EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. American Heart Journal 75: 752–758, 1968
Savage DD, Garrison RJ, Castelli WP, et al. Echocardiographic left ventricular hypertrophy in the general population is associated with increased 2-year mortality, independent of the standard risk factors — the Framingham Heart Study. American Heart Association Council of Cardiovascular Epidemiology Newsletter Abstract 37: 33, 1985
Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertophy as obtained by unipolar precordial and limb leads. American Heart Journal 37: 16–86, 1949
Soufer R, Wohlgelernter D, Vita NA, Amnchestequi M, Sostman HD, et al. Intact systolic left ventricular function in clinical congestive heart failure. American Journal of Cardiology 55: 1032–1036, 1985
Tarazi RC. Regression of left ventricular hypertrophy by medical treatment: present status and possible implications. American Journal of Medicine (Suppl. 3a): 80–86, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levy, D. Left Ventricular Hypertrophy. Drugs 35 (Suppl 5), 1–5 (1988). https://doi.org/10.2165/00003495-198800355-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800355-00002